Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05307783




Registration number
NCT05307783
Ethics application status
Date submitted
23/03/2022
Date registered
1/04/2022
Date last updated
13/10/2023

Titles & IDs
Public title
EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging
Scientific title
A Multicenter Observational Study to Evaluate Outcomes of EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging
Secondary ID [1] 0 0
EGE-P4-21-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hemorrhage 0 0
Bleeding Hemorrhage 0 0
Condition category
Condition code

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Devices - EmboCube Embolization Gelatin

Treatment: Devices: EmboCube Embolization Gelatin
EmboCube is a uniformly cut gelatin foam pre-loaded into a syringe, indicated for use in embolization of blood vessels to occlude blood flow to control bleeding/hemorrhaging in the peripheral vasculature
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Clinical Success: Cessation of Bleeding up to 24 hours
Timepoint [1] 0 0
24 hours
Primary outcome [2] 0 0
Incidence of device and procedure-related AEs
Timepoint [2] 0 0
24 hours

Eligibility
Key inclusion criteria
1. Age =18 years

2. Subject requires embolization and is suitable for treatment with EmboCube in
accordance with device Instructions For Use for the treatment of bleeding or
hemorrhage.

3. Subject provides written informed consent to study data collection.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Bleeding site in the neck, head, or brain.

2. Subject has co-morbidity with survival prognosis of less than 30 days, in the opinion
of the treating physician

3. In the investigator's opinion, participation in the study may not be in the subject's
best interest.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/08/2024
Actual
Sample size
Target
100
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
South Western Sydney Local Health District - Liverpool
Recruitment hospital [3] 0 0
Alfred Health - Sydney
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
- Liverpool
Recruitment postcode(s) [3] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
France
State/province [1] 0 0
Nîmes
Country [2] 0 0
France
State/province [2] 0 0
Paris

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merit Medical Systems, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multicenter, observational study of the use of EmboCube Embolization Gelatin to
control hemorrhaging and bleeding. The study is designed to enable the collection, analysis,
and reporting of data from "real-world" use of EmboCube used in accordance with the
Instructions for Use (IFU) associated with the product's CE Mark approval.

Data collection will include that relating to safety and effectiveness and the period of
observation during which data will be collected will extend from the index procedure through
28 days post procedure.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05307783
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Irene Coughlin
Address 0 0
Country 0 0
Phone 0 0
13857669133
Fax 0 0
Email 0 0
irene.coughlin@merit.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05307783